Celltrion Wins European Approval for Phase 3 Zymfentra Trial in Rheumatoid Arthritis

• Celltrion received European approval on Oct. 30, 2026, for a Phase 3 trial of CT-P13 SC (Zymfentra) in rheumatoid arthritis.
• The placebo-controlled trial will enroll 296 patients for 52 weeks of treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celltrion Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102800302), on November 02, 2026, and is solely responsible for the information contained therein.